Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional safety and efficacy in a Phase 2b study. A 50-milligram dose of efruxifermin resulted in the reversal of cirrhosis in 39% of the patients while none of them experienced any further worsening of MASH,…
India has experienced a remarkable rally in its stock markets since the end of the pandemic, with the country’s…
Early Monday trading saw sharp declines across the US stock market, triggered by the unexpected rise of a Chinese…
DeepSeek – a China-based startup wreaked havoc on the US-listed stocks today following reports that its latest AI model…
DeepSeek, the Chinese artificial intelligence startup, has been hit by “large-scale malicious attacks”. To mitigate the impact, it has…
Bitcoin has clawed its way back to well over $100,000 following a brief decline in tandem with the US…
Investors are often cautioned against investing in stocks ahead of their earnings. But there are a few of them…
US President Donald Trump has announced a $500 billion artificial intelligence initiative dubbed Stargate in collaboration with Oracle, SoftBank,…
Trading activity for Russian oil due for March delivery has slowed in Asia, the primary market, Reuters reported on…